SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Olsen Jorgen H)
 

Search: WFRF:(Olsen Jorgen H) > (2015-2019) > Effect of simvastat...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003663naa a2200481 4500
001oai:DiVA.org:umu-150715
003SwePub
008180816s2018 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1507152 URI
0247 a https://doi.org/10.1016/j.atherosclerosis.2018.03.0302 DOI
040 a (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Hodges, Gethin W.4 aut
2451 0a Effect of simvastatin and ezetimibe on suPAR levels and outcomes
264 1b ELSEVIER IRELAND LTD,c 2018
338 a print2 rdacarrier
520 a Background and aims: Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory marker associated with cardiovascular disease. Statins lower both low-density lipoprotein (LDL)-cholesterol and C-reactive protein (CRP), resulting in improved outcomes. However, whether lipid-lowering therapy also lowers suPAR levels is unknown.& para;& para;Methods: We investigated whether treatment with Simvastatin 40 mg and Ezetimibe 10 mg lowered plasma suPAR levels in 1838 patients with mild-moderate, asymptomatic aortic stenosis, included in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study, using a pattern mixture model. A 1-year Cox analysis, adjusted for established cardiovascular risk factors, allocation to study treatment, peak aortic valve velocity and baseline suPAR, was performed to evaluate relationships between change in suPAR with all-cause mortality and the composite endpoint of major cardiovascular events (MCE) composed of ischemic cardiovascular events (ICE) and aortic valve related events (AVE).& para;& para;Results: After 4.3 years of follow-up, suPAR levels had increased by 9.2% (95% confidence interval [CI]: 7.0%-11.5%) in the placebo group, but only by 4.1% (1.9%-6.2%) in the group with lipid-lowering treatment (p<0.001). In a multivariate 1-year analysis, 1-year suPAR was strongly associated with all-cause mortality, hazard ratio (HR) = 2.05 (1.17-3.61); MCE 1.40 (1.01-1.92); and AVE 1.42 (1.02-1.99) (all p<0.042) for each doubling of suPAR; but was not associated with ICE.& para;& para;Conclusions: Simvastatin and Ezetimibe treatment impeded the progression of the time-related increase in plasma suPAR levels. Year-1 suPAR was associated with all-cause mortality, MCE, and AVE irrespective of baseline levels (SEAS study: NCT00092677). (C) 2018 Elsevier B.V. All rights reserved.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a Atherosclerosis
653 a Biomarker
653 a Cardiovascular disease
653 a Cardiovascular risk
653 a Inflammation
653 a Statins
653 a SuPAR
7001 a Bang, Casper N.4 aut
7001 a Forman, Julie L.4 aut
7001 a Olsen, Michael H.4 aut
7001 a Boman, Kurtu Umeå universitet,Medicin4 aut0 (Swepub:umu)kubo0001
7001 a Ray, Simon4 aut
7001 a Kesaniemi, Y. Antero4 aut
7001 a Eugen-Olsen, Jesper4 aut
7001 a Greve, Anders M.4 aut
7001 a Jeppesen, Jorgen L.4 aut
7001 a Wachtell, Kristian4 aut
7102 a Umeå universitetb Medicin4 org
7730 t Atherosclerosisd : ELSEVIER IRELAND LTDg 272, s. 129-136q 272<129-136x 0021-9150x 1879-1484
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-150715
8564 8u https://doi.org/10.1016/j.atherosclerosis.2018.03.030

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view